RSV Risk: Who Is Most Vulnerable to Severe Infection?
Respiratory syncytial virus (RSV) is a ubiquitous seasonal virus causing mild, cold-like illness in most healthy children and adults. However, it is the leading cause of lower respiratory tract infection (LRTI)—bronchiolitis and pneumonia—in infants and a major cause of severe respiratory disease in older adults and immunocompromised individuals.
Highest-Risk Groups for Severe RSV
- Infants and young children: Especially under 6 months (peak hospitalization age 2–3 months). Immature airways, small caliber, limited immune memory.
- Premature infants (born <37 weeks, especially <29 weeks): Underdeveloped lungs, reduced maternal antibody transfer.
- Children with underlying conditions: Congenital heart disease (especially hemodynamically significant), chronic lung disease of prematurity (BPD), neuromuscular disorders, immunodeficiency, Down syndrome.
- Older adults (≥65 years): Age-related immune senescence, comorbidities, reduced respiratory reserve. RSV causes ~60,000–160,000 hospitalizations and 6,000–10,000 deaths annually in U.S. adults ≥65.
- Immunocompromised individuals: HIV/AIDS (low CD4), hematologic malignancy, transplant recipients (solid organ, HSCT), immunosuppressive therapy (chemo, biologics, high-dose steroids).
- Adults with chronic cardiopulmonary disease: COPD, asthma, heart failure, coronary artery disease.
- Residents of long-term care facilities: High attack rates, severe outcomes.
Why These Groups?
Common threads: impaired viral clearance (immature or senescent immunity), reduced respiratory reserve (small airways, comorbidities), and dysregulated immune response causing immunopathology. RSV infects ciliated epithelial cells → sloughing, mucus plugs, bronchiolar obstruction → air trapping, atelectasis, hypoxemia.
Prevention Tools by Group
- Infants: Nirsevimab (Beyfortus®)—long-acting monoclonal antibody, single dose for all infants <8 months entering first RSV season; high-risk children 8–19 months entering second season. Palivizumab (Synagis®)—monthly IM for high-risk preemies (being replaced by nirsevimab).
- Pregnant people: Maternal RSVpreF vaccine (Abrysvo®) 32–36 weeks gestation → transplacental antibodies protect infant 0–6 months.
- Older adults (≥60): RSVpreF (Abrysvo®) or RSVPreF3 (Arexvy®) vaccines—single dose, high efficacy vs. LRTI.
- All: Hand hygiene, masking, staying home when sick, limiting infant exposure to sick contacts.
RSV is not "just a cold" for vulnerable populations. New prevention tools (maternal vaccine, infant mAb, older adult vaccines) are transformative—discuss with your provider.
Viral Infections - Related Articles
- Ebola Virus Species: Characteristics, Fatality Rates, and Geographic Distribution
- Athlete's Foot (Tinea Pedis): Symptoms, Causes & Treatment
- COVID-19 (SARS-CoV-2): Virus, Transmission, Symptoms, Treatment & Prevention
- Thread Viruses: Mechanism, Threats, and Defense Strategies
- Hepatitis B: Recognizing Early Symptoms & Understanding the Risks
- P. falciparum Malaria: Three-Day Cycle, Symptoms, and Treatment
- How Viruses Make Us Sick: Direct Damage and Immune Overreaction
